198 related articles for article (PubMed ID: 22924757)
1. Structure-activity relationships in human Toll-like receptor 8-active 2,3-diamino-furo[2,3-c]pyridines.
Salunke DB; Yoo E; Shukla NM; Balakrishna R; Malladi SS; Serafin KJ; Day VW; Wang X; David SA
J Med Chem; 2012 Sep; 55(18):8137-51. PubMed ID: 22924757
[TBL] [Abstract][Full Text] [Related]
2. Structure-activity relationships in Toll-like receptor 7 agonistic 1H-imidazo[4,5-c]pyridines.
Yoo E; Crall BM; Balakrishna R; Malladi SS; Fox LM; Hermanson AR; David SA
Org Biomol Chem; 2013 Oct; 11(38):6526-45. PubMed ID: 23974333
[TBL] [Abstract][Full Text] [Related]
3. Structure-Based Design of Human TLR8-Specific Agonists with Augmented Potency and Adjuvanticity.
Beesu M; Caruso G; Salyer AC; Khetani KK; Sil D; Weerasinghe M; Tanji H; Ohto U; Shimizu T; David SA
J Med Chem; 2015 Oct; 58(19):7833-49. PubMed ID: 26351878
[TBL] [Abstract][Full Text] [Related]
4. Syntheses of Human TLR8-Specific Small-Molecule Agonists.
Beesu M; Kokatla HP; David SA
Methods Mol Biol; 2017; 1494():29-44. PubMed ID: 27718184
[TBL] [Abstract][Full Text] [Related]
5. Optimization of 8-oxoadenines with toll-like-receptor 7 and 8 activity.
Bazin HG; Bess LS; Livesay MT; Li Y; Cybulski V; Miller SM; Johnson DA; Evans JT
Bioorg Med Chem Lett; 2020 Mar; 30(6):126984. PubMed ID: 32001135
[TBL] [Abstract][Full Text] [Related]
6. Further exploration of the structure-activity relationship of imidazoquinolines; identification of potent C7-substituted imidazoquinolines.
Hunt JR; Kleindl PA; Moulder KR; Prisinzano TE; Forrest ML
Bioorg Med Chem Lett; 2020 Jan; 30(2):126788. PubMed ID: 31784317
[TBL] [Abstract][Full Text] [Related]
7. Exquisite selectivity for human toll-like receptor 8 in substituted furo[2,3-c]quinolines.
Kokatla HP; Sil D; Malladi SS; Balakrishna R; Hermanson AR; Fox LM; Wang X; Dixit A; David SA
J Med Chem; 2013 Sep; 56(17):6871-85. PubMed ID: 23899291
[TBL] [Abstract][Full Text] [Related]
8. Human Toll-like receptor 8-selective agonistic activities in 1-alkyl-1H-benzimidazol-2-amines.
Beesu M; Malladi SS; Fox LM; Jones CD; Dixit A; David SA
J Med Chem; 2014 Sep; 57(17):7325-41. PubMed ID: 25102141
[TBL] [Abstract][Full Text] [Related]
9. Structure-based design of novel human Toll-like receptor 8 agonists.
Kokatla HP; Sil D; Tanji H; Ohto U; Malladi SS; Fox LM; Shimizu T; David SA
ChemMedChem; 2014 Apr; 9(4):719-23. PubMed ID: 24474703
[TBL] [Abstract][Full Text] [Related]
10. Toll-like receptor-8 agonistic activities in C2, C4, and C8 modified thiazolo[4,5-c]quinolines.
Kokatla HP; Yoo E; Salunke DB; Sil D; Ng CF; Balakrishna R; Malladi SS; Fox LM; David SA
Org Biomol Chem; 2013 Feb; 11(7):1179-98. PubMed ID: 23314908
[TBL] [Abstract][Full Text] [Related]
11. Structure-Based Design of Highly Potent Toll-like Receptor 7/8 Dual Agonists for Cancer Immunotherapy.
Wang Z; Gao Y; He L; Sun S; Xia T; Hu L; Yao L; Wang L; Li D; Shi H; Liao X
J Med Chem; 2021 Jun; 64(11):7507-7532. PubMed ID: 34048243
[TBL] [Abstract][Full Text] [Related]
12. The Imidazoquinoline Toll-Like Receptor-7/8 Agonist Hybrid-2 Potently Induces Cytokine Production by Human Newborn and Adult Leukocytes.
Ganapathi L; Van Haren S; Dowling DJ; Bergelson I; Shukla NM; Malladi SS; Balakrishna R; Tanji H; Ohto U; Shimizu T; David SA; Levy O
PLoS One; 2015; 10(8):e0134640. PubMed ID: 26274907
[TBL] [Abstract][Full Text] [Related]
13. Oligodeoxynucleotides differentially modulate activation of TLR7 and TLR8 by imidazoquinolines.
Gorden KK; Qiu X; Battiste JJ; Wightman PP; Vasilakos JP; Alkan SS
J Immunol; 2006 Dec; 177(11):8164-70. PubMed ID: 17114492
[TBL] [Abstract][Full Text] [Related]
14. Toll-like receptor 7 selective synthetic oligoribonucleotide agonists: synthesis and structure-activity relationship studies.
Lan T; Dai M; Wang D; Zhu FG; Kandimalla ER; Agrawal S
J Med Chem; 2009 Nov; 52(21):6871-9. PubMed ID: 19824640
[TBL] [Abstract][Full Text] [Related]
15. Synthetic oligoribonucleotides-containing secondary structures act as agonists of Toll-like receptors 7 and 8.
Lan T; Putta MR; Wang D; Dai M; Yu D; Kandimalla ER; Agrawal S
Biochem Biophys Res Commun; 2009 Aug; 386(3):443-8. PubMed ID: 19523922
[TBL] [Abstract][Full Text] [Related]
16. Discovery of GS-9688 (Selgantolimod) as a Potent and Selective Oral Toll-Like Receptor 8 Agonist for the Treatment of Chronic Hepatitis B.
Mackman RL; Mish M; Chin G; Perry JK; Appleby T; Aktoudianakis V; Metobo S; Pyun P; Niu C; Daffis S; Yu H; Zheng J; Villasenor AG; Zablocki J; Chamberlain J; Jin H; Lee G; Suekawa-Pirrone K; Santos R; Delaney WE; Fletcher SP
J Med Chem; 2020 Sep; 63(18):10188-10203. PubMed ID: 32407112
[TBL] [Abstract][Full Text] [Related]
17. The use of Toll-like receptor 7/8 agonists as vaccine adjuvants.
Vasilakos JP; Tomai MA
Expert Rev Vaccines; 2013 Jul; 12(7):809-19. PubMed ID: 23885825
[TBL] [Abstract][Full Text] [Related]
18. Synthesis of 2-substituted Furo[3,2-b]pyridines Under Pd/C-Cu Catalysis Assisted by Ultrasound: Their Evaluation as Potential Cytotoxic Agents.
Laxmi DS; Vardhini SV; Guttikonda VR; Rao MVB; Pal M
Anticancer Agents Med Chem; 2020; 20(8):932-940. PubMed ID: 32160853
[TBL] [Abstract][Full Text] [Related]
19. Identification of High-Potency Human TLR8 and Dual TLR7/TLR8 Agonists in Pyrimidine-2,4-diamines.
Beesu M; Salyer AC; Brush MJ; Trautman KL; Hill JK; David SA
J Med Chem; 2017 Mar; 60(5):2084-2098. PubMed ID: 28146629
[TBL] [Abstract][Full Text] [Related]
20. Structure-activity relationships in human Toll-like receptor 2-specific monoacyl lipopeptides.
Salunke DB; Shukla NM; Yoo E; Crall BM; Balakrishna R; Malladi SS; David SA
J Med Chem; 2012 Apr; 55(7):3353-63. PubMed ID: 22385476
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
